Off-label Indication No. of patients for each indication (%) UpToDate Micromedex Guidelines
Takayasu Arteritis  27(16.2%) Effective _ Recommend[5]
Adult-onset Still’s Disease  13(7.8%) Effective _ _
Systemic Lupus Erythematosus  2(1.2%) _ _ Not Recommended[6-8]
Systemic Vasculitis  13(7.8%) _ _ Not Recommended[9, 10]
Relapsing Polychondritis  4(2.4%) Effective _ _
Behcet’s disease  8(4.8%) _ _ Recommended(Recommendation 9: nervous system involvement :limited studies have shown some efficacy of tocilizumab)[11] Recommended(IL-6 inhibitors may be effective in reducing post uveitis and macular edema in BD)[12]
Sjögren’s Syndrome  4(2.4%) _ _ Not Recommended[13, 14]
Dermatomyositis  5(3.0%) _ _ Not Recommended[15, 16]
Systemic Scleroderma  4(2.4%) Effective _ _
Neuromyelitis Optic Spectrum Disease  1(0.6%) Effective _ _
Polymyalgia Rheumatica  1(0.6%) _ _ Recommended[17, 18]
Immune-mediated Necrotizing Myopathy  1(0.6%) _ _ _
Ankylosing Spondylitis  1(0.6%) Not Effective _ Not Recommended[19]
Psoriatic Arthritis  1(0.6%) _ _ Not Recommended[20, 21]